Akero raised to Buy at Bank of America after liver drug data
Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company disclosed from a mid-stage trial for its lead drug efruxifermin against the liver disorder metabolic dysfunction-associated steatohepatitis (MASH).
Akero Therapeutics Stock Doubles on Liver Data
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically intended to treat MASH.
Akero Therapeutics’ Efruxifermin Shows Promise: Buy Rating Backed by Upcoming SYMMETRY Data and Potential Stock Upside
Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00.Invest
Citi raises Akero Therapeutics stock target to $80 on EFX data
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while keeping a Buy rating on the stock. Currently trading at $51.71, the stock has seen remarkable momentum,
Akero Therapeutics price target raised to $73 from $56 at Canaccord
Canaccord raised the firm’s price target on Akero Therapeutics (AKRO) to $73 from $56 and keeps a Buy rating on the shares. The firm made
Akero Therapeutics Announces Proposed Public Offering of Common Stock
J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the proposed offering. The securities are being offered by Akero pursuant to an automatically effective shelf registration statement that was previously filed with the U.
STAT12h
RFK Jr.’s confirmation hearings, MASH drugs, and a controversial obesity ad
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
Akero Therapeutics upgraded to Buy from Neutral at BofA
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.8% on Analyst Upgrade
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...
American Association of Individual Investors3d
Why Akero Therapeutics, Inc.’s (AKRO) Stock Is Up 97.52%
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering. UBS Investment Bank is acting as co-manager for the offering.
biopharma-reporter2d
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Zacks.com on MSN1d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero Therapeutics Reports Positive Results from SYMMETRY Study in Recent 8-K Filing
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
Some Good MASH/NASH News From Akero Therapeutics
Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...
BioPharma Dive1d
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio ...